Yazar "Haznedaroglu, Ibrahim C." için listeleme
-
The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
Aksu, Salih; Sahin, Fahri; Uz, Burak; Yavuz, Selim A.; Atay, Hilmi; Kelkitli, Engin; Haznedaroglu, Ibrahim C. (Akad Doktorlar Yayinevi, 2012)We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose ... -
The Effect of the Chernobyl Disaster on the Occurrence of Adult Acute Leukemias in Turkey
Ozatli, Duezguen; Goeker, Hakan; Buyuhasik, Yahya; Sayinalp, Nilguen; Haznedaroglu, Ibrahim C.; Ozcebe, Osman I. (Ortadogu Ad Pres & Publ Co, 2009)Objective: The aim of this study was to investigate whether the occurrence of adulthood acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) had increased before and after the Chernobyl accident in the ... -
Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat
Uzun, Oguz; Erkan, Levent; Haznedaroglu, Ibrahim C. (Ediciones Doyma S A, 2014)Hemoptysis is symptomatic of potentially serious and life-threatening chest disease and requires urgent evaluation and treatment. The aim of this study was to evaluate the hemostatic efficacy of endobronchial application ... -
EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate
Uz, Burak; Buyukasik, Yahya; Atay, Hilmi; Kelkitli, Engin; Turgut, Mehmet; Bektas, Ozlen; Haznedaroglu, Ibrahim C. (Taylor & Francis Ltd, 2013)Objectives: The validity of the three currently used chronic myeloid leukemia (CML) scoring systems (Sokal CML prognostic scoring system, Euro/Hasford CML scoring system, and the EUTOS CML prognostic scoring system) were ... -
Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML
Malkan, Umit Y.; Aksu, Salih; Aktimur, Sude H.; Atay, Hilmi; Bektas, Ozlen; Buyukasik, Yahya; Haznedaroglu, Ibrahim C. (Akad Doktorlar Yayinevi, 2015)Unsustainable drug prices in chronic myeloid leukemia (CML) and cancer may be causing harm to patients. The aim of this multi-center study is to assess the efficacy of generic imatinib mesylate (IM) over Glivec in terms ... -
Hemostatic Efficacy of Ankaferd Blood Stopper (R) in a Swine Bleeding Model
Bilgili, Hasan; Kosar, Ali; Kurt, Mevlut; Onal, Ibrahim K.; Goker, Hakan; Captug, Ozge; Haznedaroglu, Ibrahim C. (Karger, 2009)Objective: The purpose of this study was to show the hemostatic effect of spray, solution and tampon forms of Ankaferd Blood Stopper (R) (ABS), a unique medicinal plant extract historically used as a hemostatic agent in ... -
Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study
Buyukasik, Yahya; Acar, Kadir; Kelkitli, Engin; Uz, Burak; Serefhanoglu, Songul; Ozdemir, Evren; Haznedaroglu, Ibrahim C. (Karger, 2013)Treatment of acute lymphoblastic leukemia is unsatisfactory in adults due to disease and patient-related factors and probably because adult chemotherapy regimens are weaker than pediatric protocols. Worries about inadequacy ... -
Ibrutinib: From Molecule to Medicine
Ayyildiz, Orhan; Demirkan, Fatih; Goker, Hakan; Haznedaroglu, Ibrahim C.; Ilhan, Osman; Kaynar, Leyla G.; Vural, Filiz (Akad Doktorlar Yayinevi, 2014)Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agent modulating BCR, which serves as a covalent irreversible inhibitor of BTK. Ibrutinib significantly alters the composition ... -
Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders
Aksu, Salih; Ayyildiz, Orhan; Etgul, Sezgin; Goker, Hakan; Gunes, Gursel; Haznedaroglu, Ibrahim C.; Unal, Ali (Akad Doktorlar Yayinevi, 2016)Phosphatidylinositol 3-kinases (PI3Ks) are considered as lipid kinases that are very active in the pathobiology of lymphoproliferative disorders (LPDs). Idelalisib, a selective inhibitor of the delta isoform of PI3K, ... -
The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases
Aktimur, Sude H.; Malkan, Umit Y.; Eyupoglu, Damla N.; Haznedaroglu, Ibrahim C.; Kelkitli, Engin; Atay, Hilmi M.; Turgut, Mehmet (Akad Doktorlar Yayinevi, 2016)Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has ... -
In Vitro Anti-Bacterial Activities of Ankaferd Medicinal Plant Extract
Akkoc, Nefise; Akcelik, Mustafa; Haznedaroglu, Ibrahim C.; Goker, Hakan; Turgut, Mehmet; Aksu, Salih; Firat, H. Cahit (Ortadogu Ad Pres & Publ Co, 2009)Objective: The medicinal value of plants lies in some chemical substrates that produce a definitive physiological action on the human body. Ankaferd comprises a standardized mixture of the plants Thymus vulgaris, Glycyrrhiza ... -
Topical Ankaferd Bloodstopper in the Management of Critical Bleedings due to Hemorrhagic Diathesis
Turgut, Mehmet; Tutkun, Ferda; Celebi, Nukhet; Muglali, Mehtap; Haznedaroglu, Ibrahim C.; Goker, Hakan (Akad Doktorlar Yayinevi, 2011)Ankaferd BloodStopper (R) (ABS) is an herbal extract which has been used historically as a haemostatic agent in traditional Turkish medicine. ABS comprises of standardized mixture of herbs Thymus vulgaris, Glycyrrhiza ...
